{"links":{"feed":"https://www.erudio.com/reports/bicar-nct04703686/feed.json","html":"https://www.erudio.com/reports/bicar-nct04703686","json":"https://www.erudio.com/reports/bicar-nct04703686.json","markdown":"https://www.erudio.com/reports/bicar-nct04703686.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"bicar-nct04703686"}},"request":"https://www.erudio.com/contact?report=bicar-nct04703686"},"offer":{"cited_clinicians":0,"cited_commentary_sources":4,"verified_hcp_statements":68,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":1},"for_sale":false,"one_off_usd":null,"not_for_sale":{"note":"This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it; a later edition that reaches the minimum is for sale at its normal price.","contact":"https://www.erudio.com/contact?report=bicar-nct04703686","email":"hello@erudio.com"},"purchase":{"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=bicar-nct04703686","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/bicar-nct04703686","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 68 verified statements · none from confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":null,"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-17T06:44:47.324374Z","notify_subscribers":false,"status":"corrected","summary":"taxonomy mapping corrected"},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":8,"no_commentary_found":1},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Overall Survival"},{"claim_count":2,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":1,"title":"Secondary endpoints"},{"claim_count":4,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":4,"title":"Population and setting"},{"claim_count":3,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":1,"title":"The comparison"},{"claim_count":3,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":2,"title":"Safety and tolerability"},{"claim_count":2,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":1,"title":"Design and conduct"},{"claim_count":7,"coverage":"discussed","id":"A1","source_count":2,"title":"Accelerated ramp-up, treatment urgency and its unproven incremental benefit"},{"claim_count":11,"coverage":"discussed","id":"A2","source_count":1,"title":"Translation to high-risk, physician-selected practice"},{"claim_count":2,"coverage":"discussed","id":"A3","source_count":1,"title":"Bridging before CAR-T or transplantation"}],"counts":{"beyond_population_findings":1,"beyond_population_statements":9,"cited_clinicians":0,"cited_clinicians_by_role":{},"cited_physicians":0,"cited_sources":6,"claims_by_expression_type":{"comparison":11,"experience":8,"interpretation":16,"opinion":14,"primary_context":6,"question":1,"restatement":6,"uncertainty":6},"claims_by_kind":{"objective_result":3,"protocol_statement":3,"publication_statement":35,"source_observation":27},"clinician_statements":0,"evidence_units":25,"findings":3,"people_cited":3,"people_identity_verified":1,"people_total":3,"screened_sources":7,"verified_claims":68},"findings_index":[{"cited_clinicians":0,"id":"F1","structure":{"claims":18,"claims_by_group":{"comparisons":3,"experience":2,"questions":2,"restated":4,"views":7},"limitations":3,"links":{"context":3,"support":18},"ma_question":true,"named_voices":1,"passages":10,"sources":4,"sources_by_kind":{"media":2,"publication":2}},"title":"Accelerated RO7082859 ramp-up: what speakers say","evidence_line":"18 statements from 1 speaker in 4 sources, 2 of them podcasts or videos"},{"cited_clinicians":0,"id":"F2","structure":{"claims":21,"claims_by_group":{"comparisons":2,"experience":0,"questions":2,"restated":7,"views":10},"limitations":5,"links":{"context":4,"support":21},"ma_question":true,"named_voices":2,"passages":13,"sources":5,"sources_by_kind":{"commentary":2,"media":1,"publication":2}},"title":"RO7082859 after CAR-T: a speaker welcomes its activity, but says work remains","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-e7d8591b7d2d2d753cf8"],"clause":"say work remains","holders":1},"cited_claim_ids":["claim-e7d8591b7d2d2d753cf8","claim-7f8fd2982f02c39d9ccd","claim-e2b360c8eda020b4cb86","claim-ffb7677e99aa099a5d8f","claim-ba9a6da03adcc53d0f18"],"clinicians":false,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"21 statements from 2 speakers in 5 sources, 1 of them a podcast or video","holder_line":"1 of the 2 named speakers in this finding holds this view; 1 of them holds its caveat, “say work remains”"},{"cited_clinicians":0,"id":"F3","population":"beyond","structure":{"claims":15,"claims_by_group":{"comparisons":2,"experience":8,"questions":1,"restated":1,"views":3},"limitations":5,"links":{"context":0,"support":16},"ma_question":true,"named_voices":1,"passages":4,"sources":2,"sources_by_kind":{"media":1,"publication":1}},"title":"Fast ramp-up in high-risk DLBCL: a speaker finds it feasible but asks who benefits","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-92954246e9e07a7ba1c5"],"clause":"ask who benefits","holders":1},"cited_claim_ids":["claim-92954246e9e07a7ba1c5"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"15 statements from 1 speaker in 2 sources, 1 of them a podcast or video","holder_line":"The one named speaker in this finding holds this view; 1 of them holds its caveat, “ask who benefits”"}],"open_question":{"reason":"No question clinicians left open passed this edition's checks and review.","status":"unavailable"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One round-table assessment welcomes faster dosing; a results publication leaves added efficacy open"},{"id":"section-2","level":2,"title":"A relayed ASH23 assessment welcomes activity but says work remains"},{"id":"section-3","level":2,"title":"Beyond the trial population"},{"id":"section-4","level":3,"title":"One speaker considers BiCAR-like acceleration feasible but calls for better selection in high-risk practice"},{"id":"section-5","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, na, single group, phase2","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Overall Survival"},{"findings":[{"id":"F2","shared_claims":2}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":3}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":3}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-17T06:44:47.324374Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-17T18:26:34Z","record_hash":"25f399671d4018f6a024bb7a487354847e95a14460a1ced67214d7a15fb4270f","release_hash":"c3337248fe54d1fb8fe75f1be4f1de4d820d44bd8c9c20aa21ce31600c484391","report_id":"erudio-nct04703686","run_id":"80299c81-f2e3-4ae1-a383-70bdacc5f769","schema_version":"5.0","slug":"bicar-nct04703686","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"BiCAR was favored in unattributed remarks for reducing delays to full-dose treatment, an argument about urgency rather than a claim of greater benefit from acceleration. A speaker describing a separate high-risk cohort considered accelerated glofitamab feasible but attributed less benefit and more toxicity to adverse patient features. That experience warrants caution about extending use rather than contradicting the trial’s safety findings; the speaker called for studies to identify who would benefit.","examples":[],"meta_description":"7 sources screened · 68 verified statements (0 from clinicians verified by NPI or staff page) from 6 sources · 3 findings. Updated Nov 17, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-17T18:26:34Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-11-17T20:19:55Z","kind":"routine","summary":"taxonomy mapping corrected"},{"affected_ids":[],"date":"2026-11-17T21:05:31Z","kind":"routine","summary":"taxonomy mapping corrected"}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":7},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on accelerated glofitamab dose escalation and cytokine release syndrome risk in relapsed or refractory lymphoma.","10 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 51 sources about other trials or topics are not included; discussion that refers to the trial only by a name it shares with other things may be missing.","Most substantive IACH remarks cannot be assigned to a named participant. They cannot be counted as additional independent speakers alongside named participants; Sarkozy's identifiable contribution is a brief affirmation.","The social-media statements include relayed material. They do not establish the relayers' independent endorsement, and reposts do not establish additional clinical agreement.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The mixed-histology ASH23 abstract summary, published DLBCL cohort and separate high-risk practice cohort are different populations. Their response, survival and toxicity figures should not be combined.","Schedule descriptions differ across the panel, interview and publication. A full protocol and an exact regulatory label for the RO7082859 alias were not available for this edition, limiting independent reconciliation.","The social-media posts and recordings reviewed do not directly assess BiCAR's own OS estimate or the choice of OS as the primary endpoint. The publication's treatment preference and methodological arguments are contextual interpretations, not evidence of independent HCP consensus.","The external-control comparison does not establish causality or superiority over an individual salvage regimen or another bispecific; residual confounding and eligibility restrictions remain material."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":0,"publication":2,"registry":0,"regulatory":0,"x_thread":1,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":4,"results":2},"count":6,"evidence_window":{"end":"2025-12-09","start":"2021-06-02"},"retrieval_snapshot":"2026-11-16T22:35:59.385946Z","timeline":[{"count":1,"week":"2021-W22"},{"count":1,"week":"2023-W44"},{"count":1,"week":"2024-W04"},{"count":1,"week":"2025-W50"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT04703686:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04703686:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:40181090","quote_policy":"short_quote_link_out"},{"id":"pubmed:42393723","quote_policy":"no_derivatives"},{"id":"openfda:df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda:20261001","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:6805965105034092544","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1508551437256642568:5b9b2bb4-7a3f-407c-a366-bde3f5e8b7b8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1720089263579267160:2a591d32-3bce-4a93-9824-0f237f0db5aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065322063372456311:10dbb34a-6218-4104-b71a-e0621cbd4ecf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065557360303628403:effc37c6-c0da-42c0-94c5-1b489ccbbb72","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:DLuIJYxS7fs","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:sZd3gn6RYHA","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":4,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":7},"count":7,"evidence_window":{"end":"2026-06-12","start":"2021-06-02"},"retrieval_snapshot":"2026-11-16T22:35:59.385946Z","timeline":[{"count":1,"week":"2021-W22"},{"count":1,"week":"2022-W13"},{"count":1,"week":"2023-W44"},{"count":1,"week":"2024-W04"},{"count":1,"week":"2025-W50"},{"count":2,"week":"2026-W24"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":2,"other":0,"podcast":0,"publication":41,"registry":0,"regulatory":0,"x_thread":2,"x_video":0,"youtube":23}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":["Gazyva"],"label":"obinutuzumab","slug":"obinutuzumab"},{"brand_names":["Columvi"],"label":"glofitamab","slug":"glofitamab"}],"indications":[{"reason":"Unmapped registry condition: Diffuse Large B-Cell Lymphoma Refractory","status":"unmapped"},{"reason":"Unmapped registry condition: Refractory Indolent Adult Non-Hodgkin Lymphoma","status":"unmapped"},{"reason":"Unmapped registry condition: Refractory Transformed B-cell Non-Hodgkin Lymphoma","status":"unmapped"},{"reason":"Unmapped registry condition: Refractory Primary Mediastinal Large B-Cell Cell Lymphoma","status":"unmapped"},{"reason":"Unmapped registry condition: Refractory Mantle Cell Lymphoma","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Diffuse large B-cell lymphoma","slug":"diffuse-large-b-cell-lymphoma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"BiCAR","aliases":["BiCAR","Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy","A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy"],"brief_title":"Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Diffuse Large B-Cell Lymphoma Refractory","Refractory Indolent Adult Non-Hodgkin Lymphoma","Refractory Transformed B-cell Non-Hodgkin Lymphoma","Refractory Primary Mediastinal Large B-Cell Cell Lymphoma","Refractory Mantle Cell Lymphoma"],"display_condition":"relapsed/refractory diffuse large B-cell lymphoma after CAR-T therapy","display_interventions":[["glofitamab","obinutuzumab"]],"enrollment":{"count":67,"type":"ACTUAL"},"interventions":[{"name":"Obinutuzumab","synonyms":["gazyva"],"type":"DRUG"},{"name":"RO7082859","synonyms":["glofitamab"],"type":"DRUG"}],"nct_id":"NCT04703686","official_title":"A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy","overall_status":"COMPLETED","phase":["PHASE2"],"primary_completion_date":{"date":"2023-01-10","type":"ACTUAL"},"primary_endpoints":[{"description":"Overall survival will be measured from the date of C1D1 of glofitamab to the date of death from any cause. Alive patients will be censored at the date of last contact","measure":"Overall Survival","timeFrame":"4 years"}],"registered_date":{"date":"2021-01-11","type":"ACTUAL"},"registry_last_updated":"2026-03-16","registry_url":"https://clinicaltrials.gov/study/NCT04703686","short_name":"BiCAR","short_name_basis":"canonical_name","sponsor":"The Lymphoma Academic Research Organisation","start_date":{"date":"2021-03-30","type":"ACTUAL"},"study_design":"interventional, na, single group, phase2","study_ids":[{"id":"BiCAR","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}